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subset of cells with enhanced tumorigenicity and chemoresis- the maintenance of stemness in liver cancer stem cells and is
tance that are called cancer stem (or stem-like) cells. We
explored the role of chromodomain-helicase-DNA-binding pro-
tein 4, which is encoded by the CHD4 gene and is known to epi-
genetically control gene regulation and DNA damage responses in
EpCAM+ liver cancer stem cells.
Methods: Gene and protein expression proﬁles were determined
by microarray and immunohistochemistry in 245 and 144 hepa-
tocellular carcinoma patients, respectively. The relationship
between gene/protein expression and prognosis was examined.
The functional role of CHD4 was evaluated in primary hepatocel-
lular carcinoma cells and in cell lines in vitro and in vivo.
Results: CHD4 was abundantly expressed in EpCAM+ hepatocel-
lular carcinoma with expression of hepatic stem cell markers
and poor prognosis in two independent cohorts. In cell lines,
CHD4 knockdown increased chemosensitivity and CHD4 overex-
pression induced epirubicin chemoresistance. To inhibit the func-
tions of CHD4 that are mediated through histone deacetylase and
poly (ADP-ribose) polymerase, we evaluated the effect of the his-
tone deacetylase inhibitor suberohydroxamic acid and the poly
(ADP-ribose) polymerase inhibitor AG-014699. Treatment with
either suberohydroxamic acid or AG-014699 reduced the number
of EpCAM+ liver cancer stem cells in vitro, and suberohydroxamic
acid and AG-014699 in combination successfully inhibited tumor
growth in a mouse xenograft model.Journal of Hepatology 20
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Hepatocellular carcinoma (HCC) is one of the most common
causes of cancer death worldwide [1,2]. This is partly due to a
lack of effective chemotherapeutic options for patients with
advanced-stage disease [3]. Various molecular proﬁling
approaches have been used to identify potential therapeutic tar-
gets which are speciﬁcally activated in HCC [4–8]. Some studies
have indicated the importance of evaluating ‘‘stemness’’ in
HCC; it reﬂects the malignant nature of the tumor and closely
correlates with a poor prognosis after surgery [9–12]. Recent evi-
dence has also suggested that HCC may conform to the cancer
stem cell (CSCs) hypothesis, which proposes that a subset of cells
with stem cell features play a fundamental role in tumor mainte-
nance and chemo/radiation resistance [13]. CSCs, also called
tumor-initiating cells or cancer stem-like cells, possess stem cell
features in their self-renewal and differentiation capacity, and
contribute to the formation of heterogeneous tumor cell popula-
tions. In HCC, several stem cell markers, including CD133, CD90,
CD13, epithelial cell adhesion molecule (EpCAM), and CD24, have
been reported to enrich side populations of CSCs [13–15]. We
recently reported that the stem cell markers EpCAM and
alpha-fetoprotein (AFP) can be used to classify HCC subtypes
with distinct gene expression proﬁles and patient prognoses
[11]. In particular, the EpCAM+ AFP+ HCC subtype shares the gene
expression features of cells from hepatic stem cell-like
(HpSC)-HCC, and exhibits resistance to the chemotherapeutic
reagent 5-ﬂuorouracil [16,17]. However, the underlying molecu-
lar mechanisms which are responsible for the chemoresistance of
EpCAM+ CSCs remain to be identiﬁed.
Using gene expression proﬁling approaches, we recently iden-
tiﬁed the activation of transcription factor Sal-like protein 4
(SALL4) in EpCAM+ CSCs from HpSC-HCC [18]. SALL4 is a15 vol. xxx j xxx–xxx
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transcription factor which plays a fundamental role in the main-
tenance of embryonic stem cells, possibly through interaction
with octamer-binding transcription factor 4, sex determining
region Y-box 2, and Nanog [19–24]. It has been reported by three
independent groups that SALL4 is a biomarker of HCCs with
stem-like gene expression signatures and a poor prognosis
[18,25,26]. SALL4 was recently found to directly interact with
the epigenetic modulator nucleosome remodeling and histone
deacetylase (NuRD) complex [27], thereby altering the histone
modiﬁcations associated with stemness. Indeed, we have demon-
strated that SALL4-positive HCCs have high histone deacetylase
(HDAC) activity and are chemosensitive to HDAC inhibitors
which reduce SALL4 expression [18].
The NuRD complex is a multi-unit chromatin remodeling
complex consisting of chromodomain-helicase-DNA-binding pro-
teins (CHDs), metastasis-associated proteins, and HDACs [28].
Interestingly, recent studies have indicated that CHD4, a
DNA-binding protein which complexes with the NuRD complex,
plays a role in the DNA damage/repair network and is recruited
to DNA-damaged sites in a poly (ADP-ribose) polymerase
(PARP)-dependent manner [29–32]. However, the role of CHD4
in the chemoresistance of EpCAM+ CSCs remains to be elucidated.
In this study, we investigated the role of CHD4, a NuRD complex
protein which regulates HDAC activity and the DNA damage
response, in the chemoresistance of liver CSCs. We further evalu-
ated the efﬁcacy of an HDAC inhibitor in combination with a
PARP inhibitor in blocking CHD4 function in EpCAM+ HCCs.Materials and methods
Clinical HCC specimens
For microarray analyses, HCC tissues were obtained from 245 patients who had
undergone radical resection from 2002 to 2003 at the Liver Cancer Institute
(Fudan University, Shanghai, China). For immunohistochemical analyses, HCC tis-
sues and adjacent non-cancerous liver tissues were obtained from 144 patients
who had undergone a hepatectomy from 2002 to 2012 at Kanazawa University
Hospital, Japan. The pathological diagnoses were performed as previously
described [12]. Of these HCC specimens, 38 were obtained fresh and
snap-frozen in liquid nitrogen for RNA analysis. An additional fresh HpSC-HCC
sample was also obtained from surgical resection and used immediately to pre-
pare a single-cell suspension. All tissue acquisition and experimental procedures
were approved by the Ethics Committee and Institutional Review Board of each
institute and conformed to the 1975 Declaration of Helsinki. All patients provided
written informed consent.
Cell culture and reagents
The human liver cancer cell lines HuH7, HuH1, Hep3B, HLE, HLF, and SK-Hep-1
were obtained from the Japanese Collection of Research Bioresources (Osaka,
Japan) or the American Type Culture Collection (Manassas, VA) and were rou-
tinely cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum (FBS). Primary HCC tissue samples were dissected
and digested with 1 lg/ml type 4 collagenase solution (Sigma–Aldrich Japan
K.K., Tokyo, Japan) at 37 C for 15 min. Contaminating red blood cells were lysed
with ammonium chloride solution (STEMCELL Technologies, Vancouver, Canada)
on ice for 10 min. CD45+ leukocytes and annexin V+ apoptotic cells were removed
from cell suspensions using an autoMACS-pro cell separator and magnet beads
(MiltenyiBiotec K.K., Tokyo, Japan). The HDAC inhibitor suberohydroxamic acid
(SBHA) and the PARP inhibitor AG-014699 were obtained from Cayman Chemical
(Ann Arbor, MI) and Selleck Chemicals (Houston, TX), respectively. Inhibitor stock
solutions were prepared in dimethyl sulfoxide and stored at 20 C until use. The
CHD4 expression plasmid pCMV6-AC-GFP-CHD4 (RG224232) was purchased
from Origene Technologies, Inc. (Rockville, MD) and the pcDNA3.1 (V790-20)
plasmid, which was used as an empty vector control, was purchased from Invit-
rogen (Carlsbad, CA). CHD4-speciﬁc and control siRNAs were purchased fromPlease cite this article in press as: Nio K et al. Defeating EpCAM+ liver cancer
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sequences were ‘‘CCCAGAAGAGGAUUUGUCA’’ and ‘‘GGUUUAAGCUCUUAGAACA’’,
respectively. The siRNA constructs were transfected using Lipofectamine 2000
(Invitrogen) in accordance with the manufacturer’s protocol.
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)
Total RNA was extracted using TRIzol (Invitrogen) in accordance with the manu-
facturer’s instructions. The expression of the selected genes was determined in
triplicate using a 7900 Sequence Detection System (Applied Biosystems, Foster
City, CA). Each sample was normalized relative to 18S ribosomal RNA expression.
The following Applied Biosystems probes used were: CHD4, Hs00172349_m1;
EPCAM, Hs00158980_m1; HDAC1, Hs02621185_sl; AFP, Hs00173490_m1; TERT,
Hs00162669_m1; BMI1, Hs00409825_g1; POU5F1, Hs03005111_g1; and 18S,
Hs99999901_s1.
Western blotting
Whole cell lysates were prepared using radio-immunoprecipitation assay (RIPA)
lysis buffer as previously described [33]. Anti-CHD4 monoclonal (Abcam, Cam-
bridge, UK) and anti-b-actin monoclonal (Sigma–Aldrich Japan K.K.) antibodies
were used for protein detection. Immune complexes were visualized using
enhanced chemiluminescence detection reagents (Amersham Biosciences Corp.,
Piscataway, NJ) in accordance with the manufacturer’s protocol.
Immunohistochemistry and immunoﬂuorescence
Immunohistochemistry was performed using an anti-CHD4 monoclonal primary
antibody (Abcam) and Envision+ kits (DAKO, Carpinteria, CA) in accordance with
the manufacturer’s instructions. CHD4 expression was evaluated and categorized
as CHD4-high (score, 4–5) or CHD4-low (score, 0–3) based on the CHD4-staining
score, which was the sum of the positivity score (0–5%, 0; 5–25%, 1; 25–50%, 2;
and >50%, 3) and staining intensity score (weak, 0; moderate, 1; and strong, 2)
for an area. Dual-color immunohistochemistry was performed using Vector red
(Vector Laboratories Inc., Burlingame, CA) and the anti-EpCAM antibody
VU-1D9 (Oncogene Research Products, San Diego, CA). For immunoﬂuorescence,
an Alexa Fluor 488-conjugated anti-mouse immunoglobulin G secondary anti-
body (Molecular Probes, Carlsbad, CA) was used. Fluorescence microscopy was
essentially performed as previously described [34]. Caspase-3 activation was
determined by immunoﬂuorescence using a cleaved caspase-3 (Asp175) antibody
(Cell Signaling Technology Inc., Danvers, MA).
Cell proliferation assays and ﬂuorescence-activated cell sorting (FACS)
For cell proliferation assays, 2  103 cells were seeded in 96-well plates and cell
proliferation was evaluated in quadruplicate using the Cell Counting Kit-8
(DOJINDO LABORATORIES, Kumamoto, Japan). For ﬂow cytometry and cell sort-
ing, cells were trypsinized, washed, and resuspended in Hank’s balanced salt solu-
tion (Lonza, Basel, Switzerland) supplemented with 1% HEPES and 2% FBS. Cells
were incubated with the FITC-conjugated anti-EpCAM monoclonal antibody
BER-EP4 (DAKO) on ice for 30 min prior to analysis using a FACSCalibur or FAC-
SAriaII (BD Biosciences, San Jose, CA).Measurement of HDAC and PARP activity
HDAC and PARP activities were measured using the Epigenase HDAC Activ-
ity/Inhibition Direct Assay Kit (Epigentek Group Inc., Farmingdale, NY) and HT
Universal Colorimetric PARP Assay Kit (Trevigen Inc., Gaithersburg, MD), respec-
tively. Brieﬂy, nuclear proteins were extracted using NE-PER Nuclear and Cyto-
plasmic Extraction Reagents (Thermo Fisher Scientiﬁc KK, Tokyo, Japan) and
HDAC and PARP activity was measured in triplicate. Calculations were performed
in accordance with the manufacturers’ protocols.Animal studies
Cells (1  105 HuH7 or primary HCC cells, or 3  106 HLF cells) were resuspended
in 200 ll of a 1:1 DMEM: Matrigel (BD Biosciences) mixture and subcutaneously
injected into 6-week-old non-obese diabetic/severe combined immunodeﬁciency
mice (NOD/NCrCRl-Prkdcscid) which were purchased from Charles River
Laboratories, Inc. (Wilmington, MA). For each cell type, 20 mice were inoculated.stem cells by targeting chromatin remodeling enzyme CHD4 in human
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The experimental protocol was approved by the Kanazawa University Animal
Care and Use Committee and conformed to the Guide for the Care and Use of
Laboratory Animals prepared by the National Academy of Sciences. The size
and prevalence of subcutaneous tumors were recorded as previously described
[34]. Once tumors had reached approximately 100 mm3 (HuH7 and primary
HCC cells) or 50 mm3 (HLF cells), mice were randomized into treatment groups
(n = 5 in each group). Mice were intraperitoneally injected with vehicle, 10 mg/kg
AG-014699, 200 mg/kg SBHA, or AG-014699 and SBHA 3 times a week for
14 days.
Microarray studies and statistical analysis
Affymetrix U133A2.0 gene expression data were obtained from the National
Center for Biotechnology Information Gene Expression Omnibus database (GEO
accession number GSE14520), as previously described [35]. The BRB-ArrayTools
software (version 4.3.2) was used for class comparison analyses. Hierarchical
clustering analysis was performed using GENESIS software (version 1.7.6). To
compare treatment groups in cell proliferation and qRT-PCR assays, Student’s t
tests and Chi-square tests were performed in GraphPad Prism software 6.0
(GraphPad Software, San Diego, CA). Kaplan–Meier survival analysis was also per-
formed in GraphPad Prism software 6.0 (GraphPad Software). Univariate and
multivariate Cox proportional hazards regression analysis was performed using
SPSS software (SPSS Inc., Chicago, IL).CHD4-high
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Fig. 1. High expression of chromodomain-helicase-DNA-binding protein 4
(CHD4) in epithelial cell adhesion molecule (EpCAM)+ cancer stem cells (CSCs).
(A) Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)
analysis of CHD4 and EpCAM in HuH7 cells. EpCAM+ and EpCAM HuH7 cells
were isolated by FACS sorting; (B) Immunoﬂuorescence analysis of CHD4 in
EpCAM+ and EpCAM HuH7 cells (scale bar, 50 lm). (C) Immunohistochemical
analysis of CHD4 in surgically resected hepatocellular carcinomas (HCCs).
Representative photomicrographs of CHD4-high (right panel) and CHD4-low (left
panel) HCC tissues are shown (scale bar, 100 lm). (D) Kaplan–Meier survival
curves for 144 patients who underwent surgery. CHD4-high HCCs (n = 50)
showed a poor prognosis compared with CHD4-low HCCs (n = 94).Results
High expression of CHD4 in EpCAM+ liver CSCs
We evaluated the expression of CHD4 in EpCAM+ and EpCAM
cells using a HuH7 single-cell suspension. We found that CHD4
was up-regulated in EpCAM+ cells compared with EpCAM- cells
(Fig. 1A). Using immunoﬂuorescence imaging, a strong nuclear
accumulation of CHD4 was identiﬁed in the isolated EpCAM+ cells
(Fig. 1B and Supplementary Fig. 1A). Similar results were also
observed in puriﬁed EpCAM+ and EpCAM cells obtained from a
primary HCC specimen (Supplementary Fig. 1B). To explore the
relationship between CHD4 and EpCAM expression in HCC and
conﬁrm the nuclear accumulation of CHD4 in HCC tissues, we
analyzed 144 surgically resected HCC specimens (cohort 1) using
immunohistochemistry. Interestingly, the abundance of CHD4+
cells varied dramatically in each HCC specimen (Fig. 1C). We eval-
uated the expression of CHD4 in terms of staining intensity and
the number of positively stained cells, and categorized HCC tis-
sues as CHD4-high or CHD4-low according to the criteria
described in the Materials and methods section. Using these cri-
teria, 50 of the 144 HCCs (34.7%) were classiﬁed as CHD4-high
HCCs. An analysis of the clinicopathological characteristics of
CHD4-high and CHD4-low HCCs suggested that the CHD4-high
HCCs were signiﬁcantly associated with a poorly differentiated
morphology, large tumor size, and EpCAM and CK19 expression
(Table 1). The co-expression of CHD4 and EpCAM in HCC tissues
was conﬁrmed by dual-color immunohistochemical analysis
(Supplementary Fig. 1C). Kaplan–Meier survival analysis indi-
cated that, following surgery, CHD4-high HCCs are statistically
signiﬁcantly associated with a poorer survival compared to
CHD4-low HCCs (p = 0.036; Fig. 1D). Given that the expression
of CHD4 and EpCAM did not completely overlap in the HCC sam-
ples (Table 1), we performed a separate evaluation of the effect of
CHD4 expression on the survival of EpCAM+ and EpCAM HCC
patients (Supplementary Fig. 1D). As expected, CHD4-low
EpCAM HCCs showed better survival than other subclasses.
CHD4-high EpCAM+ HCCs showed a worse prognosis than
CHD4-low EpCAM+ HCCs, but this difference was not statistically
signiﬁcant. Interestingly, CHD4-high EpCAM HCCs showed aPlease cite this article in press as: Nio K et al. Defeating EpCAM+ liver cancer
hepatocellular carcinoma. J Hepatol (2015), http://dx.doi.org/10.1016/j.jhep.2
Journal of Hepatology 201worse prognosis than CHD4-low EpCAM HCCs, and this differ-
ence was statistically signiﬁcant (p = 0.03). These analyses sug-
gest that CHD4 expression impacts HCC survival, even in
EpCAM HCCs. We therefore evaluated the prognostic value of
CHD4 expression on survival, relative to other clinicopathological
parameters, in cohort 1 using univariate and multivariate Cox
regression analysis (Supplementary Tables 1 and 2). Although
high CHD4 expression, tumor size, portal vein invasion, Barcelona
Clinic Liver Cancer (BCLC) stage, histology, and serum AFP were
all associated with a poor survival in univariate analysis, multi-
variate analysis indicated that only the BCLC stage was an inde-
pendent risk factor for poor survival in HCC. This suggests that
CHD4 expression might be a confounding factor in HCC and is
not sufﬁcient, on its own, for evaluating the survival outcome
of HCC.
Transcriptomic characteristics of CHD4-high HCCs
To evaluate the molecular proﬁles of CHD4-high HCCs, we ana-
lyzed an Affymetrix gene expression dataset of 245 primary
HCC tissues (cohort 2). We deﬁned top-tertile of all HCCs (83 of
245) as CHD4-high when ordered according to the CHD4 signal
intensities. The difference between CHD4 gene expression instem cells by targeting chromatin remodeling enzyme CHD4 in human
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Table 1. Clinicopathological characteristics of CHD4-high and CHD4-low HCCs.
Parameter CHD4-high (n = 50) CHD4-low (n = 94) p value*
Mean age, y (SD) 62.8 (9.5) 63.6 (9.9) 0.63
Sex: male/female 37/13 67/27 0.85
Mean AFP level, ng/ml (SD) 9931 (55,278) 639.5 (2220) 0.11
Histologic grade??: I−II/II−III/III−IV 5/30/15 16/71/7 0.0014
Mean tumor size, mm (SD) 41.8 (28.2) 31.6 (19.0) 0.048
Macroscopic portal vein invasion: yes/no 14/36 18/76 0.29
BCLC stage: 0/A/B/C 4/23/7/16 20/47/7/20 0.09
Virus status: B/C/B + C/NBNC 17/22/2/9 21/57/1/15 0.19
EpCAM: positive/negative 26/24 30/64 0.02
CK19: positive/negative 15/35 9/85 0.004
CHD4, chromodomain-helicase-DNA-binding protein 4; HCC, hepatocellular carcinoma; SD, standard deviation; AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer;
B, hepatitis B surface (HBs) antigen positive; C, hepatitis C virus (HCV) antibody positive; B + C; HBs antigen positive and HCV antibody positive; NBNC, HBs antigen
negative and HCV antibody negative; EpCAM, epithelial cell adhesion molecule.
⁄Mann–Whitney U test, Chi-square test, or Fisher’s exact test.
⁄⁄Edmondson–Steiner grading.
Research ArticleCHD4-high and CHD4-low HCCs was 1.62-fold (Supplementary
Fig. 2A). Similarly, the difference between CHD4 gene expression
in CHD4-high and CHD4-low HCCs deﬁned by immunohisto-
chemistry was 1.86-fold in cohort 1, evaluated by qRT-PCR
(Supplementary Fig. 2B). This demonstrates a concordance
between the gene and protein expression criteria for CHD4-high
and CHD4-low HCCs in the two cohorts. The clinicopathological
characteristics of CHD4-high and CHD4-low HCCs in cohort 2
(Supplementary Table 3) indicate that serum AFP was signiﬁ-
cantly higher in CHD4-high HCCs than in CHD4-low HCCs
(p = 0.015). We performed a class comparison analysis with t
tests (p <0.001) and permutation tests (p <0.001, computed based
on 10,000 random permutations) of the class labels (CHD4-high
and CHD4-low) using BRB-ArrayTools (version 4.3.2) to evaluate
the genes differentially expressed between the classes and to
control the number and proportion of false discoveries of genes
identiﬁed. We identiﬁed a total of 724 genes that were differen-
tially expressed with P1.2-fold difference between the two HCC
subclasses (the complete gene list with parametric p values, false
discovery rates, and permutation p values of identiﬁed genes is
available in Supplementary Table 4). Of these genes, 329 were
up-regulated and 395 were down-regulated in CHD4-high HCCs
(Fig. 2A). Interestingly, stemness-related genes, such as SOX9
and KRT19, and Wnt/TGF-b pathway related genes, including
TGFB1 and TCF4, were up-regulated in CHD4-high HCCs. Genes
associated with the epigenetic control of transcription, such as
JARID1A and ARID3A, were also up-regulated in CHD4-high HCCs.
Furthermore, the genes related to mature hepatocyte function
(e.g., those involved in serum production and xenobiotic metabo-
lism), such as F8, F13B, C6, C8B, CYP4F2, and CYP2C9, were
down-regulated in CHD4-high HCCs. We proceeded to evaluate
the expression of CHD4 in EpCAM+ AFP+ HCCs (HpSC-HCCs) and
EpCAM AFP HCCs (Mature hepatocyte-like HCCs; MH-HCCs).
These are HCC subclasses which we previously proposed as being
associated with the stem/maturational status of HCCs [11]. As
expected, CHD4 expression was signiﬁcantly higher in
HpSC-HCCs compared with MH-HCCs (p = 0.0026; Supplemen-
tary Fig. 3). Consistent with this, pathway analysis indicated that
the Wnt/TGF-b pathway, Sin3/NuRD transcriptional regulation,
and the epigenetic regulation of gene expression were all acti-
vated in CHD4-high HCCs (Fig. 2B). In contrast, in CHD4-lowPlease cite this article in press as: Nio K et al. Defeating EpCAM+ liver cancer
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such as PPAR-regulated lipid metabolism, and cholesterol and
sphingolipid transport, were activated (Fig. 2C). The statistically
signiﬁcant poor prognosis of CHD4-high HCCs was independently
validated in the cohort 2 microarray data (p = 0.029; Fig. 2D). This
suggests that CHD4-high HCCs represent a HCC subtype with a
stem cell-like gene expression signature and a poor prognosis.
CHD4 confers chemoresistance in EpCAM+ HCCs
To evaluate the functional role of CHD4 in HCC, we transiently
knocked down CHD4 gene expression in EpCAM+ HuH7 cells
using two CHD4-speciﬁc siRNAs (CHD4#1 and CHD4#2). CHD4
expression decreased in HuH7 cells transfected with CHD4 siR-
NAs compared with those transfected with a control siRNA
(Fig. 3A). Interestingly, CHD4 knockdown enhanced chemosensi-
tivity to epirubicin in HuH7 cells (Fig. 3B). Similar results were
also obtained using HuH1 and Hep3B cells (Supplementary
Fig. 4A and 4B). We further evaluated the effect of CHD4 overex-
pression in HuH1 cells. We transfected HuH1 cells with either an
empty vector control (pcDNA 3.1) or a CHD4-encoding plasmid
(pCMV6-CHD4) and conﬁrmed the up-regulation of CHD4 tran-
script and protein (Fig. 3C). CHD4 overexpression clearly
enhanced epirubicin chemoresistance in HuH1 cells (Fig. 3D).
Again, similar results were obtained using HuH7 and Hep3B cells
(Supplementary Fig. 4C and 4D). Taken together, these data sug-
gest that CHD4 plays a pivotal role in the chemoresistance of
EpCAM+ HCC.
Overcoming EpCAM+ HCC by targeting CHD4 through HDAC/PARP
inhibition
The above data demonstrate that the activation of CHD4 may
play a fundamental role in the chemoresistance of EpCAM+ CSCs
to cytotoxic reagents, suggesting that CHD4 suppression may be
useful for the eradication of EpCAM+ CSCs. We recently demon-
strated that HDACs are activated in EpCAM+ HCCs, and that HDAC
inhibitors successfully inhibit the growth of EpCAM+ HCC cell
lines [18]. We evaluated the expression of HDAC1 in 38 surgically
resected snap-frozen specimens using qRT-PCR. The analysis
indicated a concordant up-regulation of HDAC1 in CHD4-highstem cells by targeting chromatin remodeling enzyme CHD4 in human
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Fig. 2. Transcriptome analysis of CHD4-high and CHD4-low HCCs. (A) Hierarchical cluster analysis of 726 genes withP1.2-fold difference in expression between CHD4-
high and CHD4-low HCCs. In CHD4-high HCCs, 329 genes (Cluster A) and 395 genes (Cluster B) were up-regulated and down-regulated, respectively. Each cell in the matrix
represents the expression of a gene in an individual sample. Red and green cells depict high and low expression levels, respectively, as indicated by the scale bar (fold
change in expression). EpCAM+ AFP+ HCCs (Hepatic stem cell-like HCCs; HpSC-HCCs) and EpCAM AFP HCCs (Mature hepatocyte-like HCCs; MH-HCCs) are depicted as
yellow and blue boxes, respectively. Representative genes associated with hepatic stem/maturational status are listed. (B & C) Pathway analysis of CHD4-co-regulated
genes. The signaling pathways which were activated in CHD4-high (cluster A) and CHD4-low (cluster B). HCCs with statistical signiﬁcance (p <0.01) are shown. (D) Kaplan–
Meier survival curves for 235 patients who underwent surgery. CHD4-high HCCs (n = 83) showed a poorer prognosis than CHD4-low HCCs (n = 162).
JOURNAL OF HEPATOLOGYHCCs (n = 13) compared with CHD4-low (n = 25) HCCs (p = 0.039;
Supplementary Fig. 5). Recent studies have demonstrated the role
of CHD4, in collaboration with PARP, in repairing double strand
breaks (DSBs) in cancer cells [31]. We have conﬁrmed that
CHD4 protein rapidly co-localizes with phosphorylated histone
H2AX immediately after epirubicin treatment (Supplementary
Fig. 6). Taken together, these data suggest that CHD4, with HDAC
and PARP, may maintain EpCAM+ liver CSCs by forming part of
the NuRD complex and regulating the cellular histone status
and DNA damage response. Therefore, we hypothesized that the
combination of an HDAC inhibitor with a PARP inhibitor may
be efﬁcacious in suppressing CHD4 function in EpCAM+ liver
CSCs.
We proceeded to assess HDAC and PARP activity in HuH7 cells
treated with the HDAC inhibitor SBHA and the PARP inhibitor
AG-014699; SBHA and AG-014699 suppressed HDAC and PARP
activities in HuH7 cells in a speciﬁc manner (Fig. 4A). We then
evaluated the effect of SBHA and AG-014699 on EpCAM+ CSCsPlease cite this article in press as: Nio K et al. Defeating EpCAM+ liver cancer
hepatocellular carcinoma. J Hepatol (2015), http://dx.doi.org/10.1016/j.jhep.2
Journal of Hepatology 201using ﬂuorescence-activated cell sorting. SBHA and AG-014699
treatment reduced the number of EpCAM+ CSCs compared with
control treatment (Fig. 4B). Consistent with this, the treatment
of HuH7 cells with SBHA or AG-014699 suppressed the expres-
sion of stemness-related genes such as EpCAM, AFP, TERT, BMI1,
and POU5F1, in addition to CHD4 (Fig. 4C). No additive reduction
in the population of EpCAM+ cells was observed with combined
SBHA and AG-014699 treatment (Supplementary Fig. 7). We also
evaluated the effect of AG-014699 on the early recruitment of
CHD4 to the site of DSBs. In HuH7 cells treated with epirubicin
for 30 min, AG-014699 suppressed the nuclear co-localization
of CHD4 with phosphorylated histone H2AX (Supplementary
Fig. 8).
To evaluate the chemosensitivity of CHD4-high and CHD4-low
HCCs to SBHA and AG-014699, we evaluated the expression of
CHD4 in EpCAM+ AFP+ cell lines (Hep3B, HuH7, and HuH1) and
EpCAM AFP HCC cell lines (SK-Hep-1, HLE, and HLF). Consis-
tent with the primary HCC data, EpCAM+ AFP+ HCC cell linesstem cells by targeting chromatin remodeling enzyme CHD4 in human
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Fig. 4. Effect of the histone deacetylase (HDAC) inhibitor suberohydroxamic
acid (SBHA) and the poly (ADP-ribose) polymerase (PARP) inhibitor AG-
014699 on HuH7 cells. (A) HDAC (upper panel) and PARP (lower panel) activity in
protein extracts from HuH7 cells treated with 20 lM SBHA or 15 lM AG-014699.
(B) FACS of HuH7 cells. Untreated HuH7 cells or HuH7 cells treated with 0.2
lg/ml epirubicin, 20 lM SBHA, or 15 lM AG-014699 for 7 days were stained with
a ﬂuorescein isothiocyanate–EpCAM antibody or an isotype control antibody. (C)
Upper panels: qRT-PCR analysis of HuH7 cells treated with dimethyl sulfoxide
(control) or 20 lM SBHA for 7 days. Lower panels: qRT-PCR analysis of HuH7 cells
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Epirubicin - + - + - +
p = 0.004
p = 0.0003
Fig. 3. Regulation of chemoresistance by CHD4. (A) Upper panel: qRT-PCR
analysis of HuH7 cells transfected with CHD4-speciﬁc siRNAs (CHD4#1 and
CHD4#2) or scramble control siRNA (Control). Lower panel: Western blot analysis
of HuH7 cells transfected with CHD4-speciﬁc siRNAs or scramble control siRNA.
(B) Chemosensitization of HuH7 cells by CHD4 knockdown. HuH7 cells were
transfected with CHD4-speciﬁc or control siRNAs, treated with 0.2 lg/ml
epirubicin, and cellular viability was analyzed. (C) Upper panel: qRT-PCR analysis
of HuH1 cells transfected with pcDNA3.1 control plasmid or pCMV6-AC-GFP-
CHD4 plasmid. Lower panel: Western blot analysis of HuH1 cells transfected with
pcDNA3.1 control plasmid or pCMV6-AC-GFP-CHD4 plasmid. (D) The chemore-
sistance of HuH1 cells was enhanced by CHD4 overexpression. HuH1 cells were
transfected with pcDNA3.1 control plasmid or pCMV6-AC-GFP-CHD4 plasmid,
treated with 0.2 lg/ml epirubicin, and cell viability was analyzed.
Research Articleexpressed high levels of CHD4 protein compared with
EpCAMAFP HCC cell lines (Fig. 5A). Treatment of HuH1,
HuH7, HLE, and HLF cells with 10 lM SBHA or AG-014699
indicated that both reagents inhibited the proliferation of HuH1
and HuH7 cells but had relatively little effect on the proliferation
of HLE and HLF cells (Fig. 5B and 5C). Furthermore, the combina-
tion of SBHA and AG-014699 produced an additive effect on
HuH1 and HuH7 cellular proliferation compared with either
treatment alone (Fig. 5D and 5E). The treatment of HuH7 cellsPlease cite this article in press as: Nio K et al. Defeating EpCAM+ liver cancer
hepatocellular carcinoma. J Hepatol (2015), http://dx.doi.org/10.1016/j.jhep.2
6 Journal of Hepatology 201with SBHA or AG-014699 also increased caspase-3 activation
(Supplementary Fig. 9A and 9B), indicating that the observedstem cells by targeting chromatin remodeling enzyme CHD4 in human
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Fig. 6. Suppression of HCC growth by SBHA and AG-014699 in vivo. (A) The
effect of the HDAC inhibitor SBHA and the PARP inhibitor AG-014699 on the
growth of HuH7 cells. (B) Representative images of CHD4 staining in HuH7 tumor
xenografts in control and SBHA + AG-014699-treated mice (scale bar, 100 lm).
(C) The number of nuclear CHD4-positive cells in HuH7 tumor xenografts in














































































































Fig. 5. Effect of the HDAC inhibitor SBHA and the PARP inhibitor AG-014699
on CHD4-high and CHD4-low HCC cell lines. (A) CHD4 expression in EpCAM+
alpha-fetoprotein (AFP)+ and EpCAM AFP HCC cell lines was evaluated by
Western blotting. (B) The effect of 10 lM SBHA on HuH1, HuH7, HLE, and HLF cell
growth. (C) The effect of 10 lM AG-014699 on HuH1, HuH7, HLE, and HLF cell
growth. (D & E) The effect of 20 lM SBHA and 15 lM AG-014699 on the growth of
HuH1 (D) and HuH7 (E) cells.
JOURNAL OF HEPATOLOGYinhibition of cellular proliferation with SBHA or AG-014699 treat-
ment is likely due to the stimulation of apoptosis signaling in
these cells.
Finally, we evaluated the effect of SBHA and AG-014699 com-
bination therapy on HuH7 and primary EpCAM+ HCC cells in vivo
using a subcutaneous mouse xenograft model. SBHA or
AG-014699 treatment alone had limited effects on tumor growth
compared with the control (SBHA, p = 0.3; AG-014699, p = 0.73).
However, the combination of SBHA and AG-014699 successfully
inhibited HCC tumor growth compared with control (p = 0.04)
(Fig. 6A). The number of CHD4-positive cells in tumors was also
decreased with the combination therapy compared with control
treatment (Fig. 6B and 6C). Similar results were also obtained
in primary EpCAM+ HCC cells (Supplementary Fig. 10A and
10B). Interestingly, the inhibitory effects of SBHA and
AG-014699 on tumorigenicity were not observed in EpCAM
HLF cell NOD/SCID mice tumor xenografts (Supplementary
Fig. 11).
Taken together, our data demonstrate, for the ﬁrst time, the
pivotal role of CHD4 in the maintenance and chemoresistance
of EpCAM+ CSCs. CHD4 is activated in EpCAM+ CSCs and isPlease cite this article in press as: Nio K et al. Defeating EpCAM+ liver cancer
hepatocellular carcinoma. J Hepatol (2015), http://dx.doi.org/10.1016/j.jhep.2
Journal of Hepatology 201recruited to sites of DNA damage when DSBs occur in the nucleus.
The inhibition of HDAC and PARP, using molecularly targeted
reagents, dramatically suppresses the number of EpCAM+ CSCs,
reduces CHD4 expression, and successfully inhibits EpCAM+
HCC growth.Discussion
Stemness traits in cancer cells are currently of great interest
because they may explain the malignant nature of tumors, and
therefore the clinical outcome of patients [13]. Recently, we pro-
posed a HCC classiﬁcation system based on the stem/maturation
status of tumors based on EpCAM and AFP expression [11]. These
HCC subtypes showed distinct gene expression patterns with fea-
tures resembling particular stages of liver lineages. Among them,
HpSC-HCC (EpCAM+ AFP+) was characterized by a highly invasive
nature, particularly to the vessels, chemoresistance to cytotoxic
reagents, and a poor patient prognosis after radical resection. This
highlights the need to develop a novel therapeutic approach for
this HCC subtype [17].
In the present study, we showed that CHD4, a member of the
NuRD complex together with HDAC, regulates chromatin remod-
eling and HDAC activities, and is activated in EpCAM+ CSCs. Con-
sistent with this, recent studies have indicated that epigenetic
dysregulation contributes to the maintenance of a malignant
phenotype in HCC [36,37]. The cellular abundance of CHD4 may
relate to the malignant nature of the tumor, and might thereforestem cells by targeting chromatin remodeling enzyme CHD4 in human
015.06.009
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be used to stratify HCC patient prognosis after surgery. CHD4 is a
catalytic subunit of the NuRD transcriptional repressor complex,
but recent studies have also demonstrated that CHD4 is rapidly
recruited to sites of DNA damage in a PARP-dependent manner
[29–32]. Therefore, the activation of CHD4 in CSCs may play a
dual role in maintaining stemness characteristics and enhancing
chemoresistance to DNA damage reagents.
High levels of CHD4 expression may confer resistance to
chemotherapeutic reagents which induce DSBs. Recent studies
have shown the importance of CHD4 in response to ionizing radi-
ation and PARP inhibitors [29–32,38]. In this study, we demon-
strated that CHD4 plays a role in the resistance to epirubicin,
which induces DSBs in cancer cells. Epirubicin is widely used to
treat HCC by transcatheter hepatic arterial chemoembolization,
although the utility of this treatment is considered to be limited
due to drug/hypoxia resistance in HCC cells. We have shown that
CHD4 suppression enhances epirubicin chemosensitivity in
EpCAM+ HCC cells. Given that the recruitment of PARP and
CHD4 to sites of DNA damage is believed to set up a transient
repressive chromatin structure which facilitates DNA damage
repair, our data suggest that PARP inhibitors could block NuRD
complex recruitment and facilitate DNA damage in EpCAM+ liver
CSCs.
The combination of SBHA and AG-014699 was most effective
at treating HpSC-HCC. SBHA treatment suppressed the HpSC-HCC
stemness traits with a reduction in the number of EpCAM+ cells,
and AG-014699 treatment further suppresses the recruitment of
CHD4 during the DNA damage response. A recent study has
shown that a combination therapy of HDAC and PARP inhibitors
is effective for treating HCC [39], and our ﬁndings provide mech-
anistic insights into how HDAC and PARP inhibitors work to erad-
icate EpCAM+ liver CSCs. The safety, tolerability, and efﬁcacy of
this combination therapy for HCC patients warrants further
investigation in a clinical setting.Financial support
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